CliffBio
small molecule

JADENU

DEFERASIROX

Loss of exclusivityNovember 2034latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameJADENU
Active ingredientDEFERASIROX
Strength360MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2015
Marketing statusRX

Listed patents

PatentExpiresType
9283209November 2034substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JADENU patent cliff — loss of exclusivity November 2034 | CliffBio